Table 2.
Baseline characteristics of the cohort including all individuals aged 80 years and older.
| Fourth-dose group (N = 197,052) | Third-dose group (N = 197,052) | |
|---|---|---|
| Baseline date, mean | 6 March 2022 | 6 March 2022 |
| Age, years | 85·2 (82·6-88·7) | 85·2 (82·6-88·7) |
| Female sex | 113,781 (57·7) | 116,521 (59·1) |
| Born in Sweden | 179,690 (91·2) | 176,013 (89·3) |
| Living in long-term care facility | 17,003 (8·6) | 10,738 (5·5) |
| Vaccination schedule | ||
| BNT162b2 for primary-series | 168,743 (85·6) | 159,162 (80·8) |
| BNT162b2 as third dose | 158,337 (80·4) | 156,915 (79·6) |
| BNT162b2 as fourth dose | 118,056 (59·9) | |
| mRNA-1273 as fourth dose | 78,926 (40·1) | |
Data are median (IQR) or n (%) unless otherwise specified. IQR = interquartile range.